证券代码：301213 证券简称：观想科技 公告编号：2025-010 一、董事会会议召开情况 四川观想科技股份有限公司（以下简称"公司"）于2025年4月16 日以电话、邮件、专人送达等方式发出了关于召开第四届董事会第十 二次会议的通知，会议于2025年4月27日在公司会议室以现场与通讯 相结合的方式召开。本次会议应出席表决董事7人，实际出席表决董事 7人。本次会议由董事长魏强先生召集并主持，会议的召集、出席人数、 召开程序和审议内容均符合《公司章程》及有关法律法规规定。 二、董事会会议审议情况 （一）审议通过《2024 年度董事会工作报告》 公司董事会编制了《2024 年度董事会工作报告》，并根据独立董 事出具的独立性自查文件对公司现任独立董事的独立性情况进行了 专项评估；公司独立董事分别向董事会递交了《2024 年度独立董事述 职报告》，并将在公司 2024 年年度股东大会上进行述职。 表决结果：7 票同意，0 票反对，0 票弃权，本议案获得通过。 本议案尚需提交公司 2024 年年度股东大会审议。 四川观想科技股份有限公司 第四届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实 ...

证券代码：301213 证券简称：观想科技 公告编号：2025-015 四川观想科技股份有限公司 关于2024年度不进行利润分配的专项说明公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、四川观想科技股份有限公司（以下简称"公司"）2024 年度 利润分配方案为：不派发现金红利，不送红股，不以资本公积转增股 本。 2、公司 2024 年度利润分配方案不触及《深圳证券交易所创业板 股票上市规则》规定的可能被实施其他风险警示的情形。 一、审议程序 公司于 2025 年 4 月 27 日召开第四届董事会第十二次会议及第 四届监事会第九次会议，审议通过了《关于公司 2024 年度利润分配 方案的议案》。 1、审计委员会审议情况 审计委员会认为，公司 2024 年度利润分配方案符合公司实际情 况，符合法律法规及《公司章程》的相关规定，决策程序合法、合规， 同意本次利润分配的方案。 2、董事会审议情况 公司第四届董事会第十二次会议以 7 票同意，0 票反对，0 票弃 权的审议结果通过了《关于公司 2024 年度利润分配方案的议案》。 董事会认为，公司 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 17,337,388.48, representing a 15.50% increase compared to CNY 15,011,122.33 in the same period last year[5] - Net profit attributable to shareholders increased by 25.23% to CNY 1,134,503.45 from CNY 905,928.72 year-on-year[5] - The net profit after deducting non-recurring gains and losses rose by 33.56% to CNY 998,537.90 compared to CNY 747,607.83 in the previous year[5] - Basic and diluted earnings per share increased by 25.66% to CNY 0.0142 from CNY 0.0113 year-on-year[5] - The net profit for the current period is CNY 852,247.97, an increase from CNY 662,847.51 in the previous period, representing a growth of approximately 28.6%[21] - The total profit for the current period is CNY 1,960,137.31, compared to CNY 725,704.60 in the previous period, indicating a significant increase of about 170.5%[21] - Operating profit for the current period stands at CNY 1,959,228.63, up from CNY 726,594.07, reflecting an increase of approximately 169.9%[21] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net outflow of CNY 116,978,178.47, worsening by 244.36% from a net outflow of CNY 33,970,069.04 in the same period last year[5] - Cash flow from operating activities shows a net outflow of CNY -116,978,178.47, worsening from CNY -33,970,069.04 in the previous period[24] - Cash flow from investing activities also reflects a net outflow of CNY -27,478,094.88, compared to CNY -18,213,039.65 in the previous period[25] - Cash flow from financing activities generated a net inflow of CNY 51,858,393.80, an increase from CNY 16,832,333.33 in the previous period[25] - The company reported operating cash inflows of CNY 33,310,181.90, compared to CNY 21,663,698.43 in the previous period, showing an increase of about 53.7%[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 963,893,510.44, a decrease of 1.08% from CNY 974,417,717.99 at the end of the previous year[5] - The total assets as of March 31, 2025, were CNY 963,893,510.44, down from CNY 974,417,717.99 at the beginning of the year, representing a decrease of 1.5%[18] - The total liabilities decreased to CNY 163,180,295.51 from CNY 176,006,751.03, a reduction of 7.3%[18] - The company's cash and cash equivalents decreased to CNY 262,602,652.39 from CNY 356,600,531.94 at the beginning of the year, a decline of 26.4%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 8,724, with the largest shareholder holding 42.43% of the shares[10] - The total equity attributable to shareholders of the parent company was CNY 784,988,941.62, slightly up from CNY 783,854,438.17, showing a marginal increase of 0.1%[18] Expenses - Total operating costs for Q1 2025 were CNY 18,522,290.93, up from CNY 15,391,707.41 in Q1 2024, reflecting a year-over-year increase of 20.5%[20] - Research and development expenses for Q1 2025 amounted to CNY 4,857,071.08, compared to CNY 4,380,512.08 in Q1 2024, indicating a growth of 10.9%[20] - The company reported a 1662.55% increase in income tax expenses, mainly due to an increase in deferred tax liabilities[8] Government Support - The company received government subsidies amounting to CNY 65,974.81, contributing to its financial performance[6] Contracts and Opportunities - The company secured a contract worth CNY 15,090.75 million for a project with Beijing University of Posts and Telecommunications, indicating a significant revenue opportunity[15] Other Information - The company has not executed any mergers or acquisitions during the reporting period, and the financial report is unaudited[26]

Financial Performance - The company reported a significant revenue increase of 48.77% compared to the same period last year, driven by a 259.83% growth in the core intelligent equipment business[4]. - The net profit attributable to shareholders was negative, with losses increasing compared to the previous year, primarily due to increased strategic investments in intelligent equipment and artificial intelligence[3]. - The company's operating revenue for 2024 reached ¥152,366,013.73, representing a 48.77% increase compared to ¥102,419,600.95 in 2023[19]. - The net profit attributable to shareholders was -¥8,711,453.87 in 2024, a decline of 317.80% from -¥2,085,069.62 in 2023[19]. - The net cash flow from operating activities improved significantly to ¥13,979,762.39 in 2024, compared to -¥73,485,703.94 in 2023, marking a 119.02% increase[19]. - The total assets of the company increased by 10.07% to ¥974,417,717.99 at the end of 2024, up from ¥885,264,123.81 at the end of 2023[19]. - The basic earnings per share for 2024 was -¥0.1089, a decrease of 317.24% from -¥0.0261 in 2023[19]. - The company reported a total operating revenue of ¥149,795,568.73 after deducting trade business revenue for 2024, compared to ¥100,984,559.32 in 2023[19]. - The company received government subsidies amounting to ¥4,245,536.54 in 2024, down from ¥5,414,259.95 in 2023[25]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -¥15,111,100.71 in 2024, a decline of 132.80% from -¥6,491,037.07 in 2023[19]. Strategic Focus and Development - The company plans to enhance its market competitiveness and position by leveraging new generation information technology and artificial intelligence[4]. - The company is focusing on high-quality development through military-civilian integration and aims to build an ecosystem of industry, talent, and capital[5]. - The company is committed to closely monitoring domestic and international policies and economic conditions to adapt its strategies accordingly[4]. - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts, clarifying that these do not constitute commitments to investors[5]. - The company aims to create greater value for shareholders by enhancing overall profitability through market expansion efforts[5]. Industry Insights - The software and information technology service industry, where the company operates, is a key strategic high-tech industry with no signs of overcapacity or continuous decline[5]. - The software and information technology service industry is projected to achieve a revenue target of over ¥14 trillion by 2025, with an annual growth rate exceeding 12%[30]. - The military artificial intelligence market in China is projected to exceed 80 billion yuan by 2027, with a compound annual growth rate (CAGR) of 23.5%[38]. Technological Advancements - The company focuses on integrating AI technology with military needs, establishing an "AI + military industry" innovation development model[40]. - The core product system includes a comprehensive equipment life cycle management system that enhances decision-making through data integration and analysis[44]. - The company has developed four technological pillars: autonomous controllable information technology, AI empowerment system, digital twin technology, and flexible intelligent equipment capabilities[41]. - The company aims to optimize the military technology structure and product structure through deep integration of new-generation AI technology with defense technology[38]. - The company emphasizes a management strategy of "small core, large periphery" to strengthen ecosystem construction and optimize the industrial chain[42]. Product Development and Innovation - The smart equipment business includes cutting-edge products such as drones and unmanned vehicles, demonstrating significant potential in both military and civilian applications[52]. - The self-developed smart brain system provides core functions for intelligent equipment, including environmental perception and automatic control, enhancing the reliability and integration of control units[53]. - The company has developed a digital repair solution that integrates advanced digital technologies, achieving comprehensive intelligent management of the equipment repair process[46]. - The digital equipment management system allows for real-time monitoring of repair progress and key indicators through an intuitive graphical interface[46]. - The company has established a complete technical system based on data collection, digital modeling, and digital twin support, enhancing the entire lifecycle management of equipment[48]. Financial Management and Governance - The company has established a strict quality management system to ensure product reliability and quality, which is critical in the complex and variable application environments of military products[89]. - The company has a governance structure that includes a clear distinction between independent and executive directors[182]. - The board's composition and changes reflect a commitment to maintaining effective oversight and management practices[181]. - The company has maintained a zero compensation policy for board members, ensuring alignment with shareholder interests[200]. Market Expansion and Client Diversification - The company aims to diversify its client base by expanding into non-military sectors to reduce dependency on a single industry and mitigate seasonal revenue risks[161]. - The company is focused on expanding its market presence and enhancing its product offerings through strategic management[198]. - The company plans to strengthen strategic partnerships with leading domestic enterprises to expand market share and enhance technological innovation[146]. Research and Development - The company's R&D expenses for 2024 were ¥33,967,823.43, accounting for 22.29% of operating revenue, a decrease from 32.28% in 2023[116]. - The number of R&D personnel increased by 4.94% to 85, with a notable rise in the proportion of personnel aged 30 and below[116]. - The company is investing 50 million in R&D for new technologies aimed at enhancing product offerings[200]. Risk Management - The company faces risks from external environmental changes, particularly in the defense sector, and will align its strategies with national priorities[154]. - A complex organizational structure has increased management and control risks, prompting the company to enhance its internal governance mechanisms[158].

| 300051 | 琏升科 | 19.94 | 14.66 | 2837.12 | 7.20 | | --- | --- | --- | --- | --- | --- | | | 技 | | | | | | 000676 | 智度股 | 1.96 | 2.27 | 1990.28 | 8.89 | | | 份 | | | | | | 002474 | 榕基软 | 3.76 | 3.56 | 1772.34 | 14.89 | | | 件 | | | | | | 300166 | 东方国 | 3.62 | 3.51 | 1686.77 | 5.35 | | | 信 | | | | | | 300287 | 飞利信 | 3.62 | 4.31 | 1607.77 | 5.30 | | 600986 | 浙文互 | 3.71 | 3.55 | 1601.51 | 4.08 | | | 联 | | | | | | 002152 | 广电运 通 | 2.40 | 1.24 | 1404.79 | 3.71 | | 002354 | 天娱数 科 | 4.24 | 4.51 | 1291.46 | 3.18 | | 6 ...

Group 1 - The core viewpoint of the articles highlights the performance and financial metrics of Guo Xin Health, indicating a recent stock price increase and a significant market capitalization of 10.353 billion yuan [1] - As of April 21, Guo Xin Health's stock closed at 10.55 yuan, reflecting a 1.15% increase, with a price-to-book ratio of 7.45 [1] - The company experienced a net outflow of 2.9771 million yuan in principal funds on April 21, but overall, there was a net inflow of 18.1082 million yuan over the past five days [1] Group 2 - Guo Xin Health's primary business areas include digital medical insurance, digital healthcare, digital pharmaceuticals, and health services, with key products and services in drug and medical device bidding agency, digital medical insurance, digital pharmaceuticals, and digital healthcare [1] - The company's "Four Libraries and Twenty-Four Systems" knowledge system is recognized in the industry as the "Four Libraries Encyclopedia" [1] - For the third quarter of 2024, Guo Xin Health reported an operating income of 200 million yuan, a year-on-year increase of 24.40%, while the net profit was -30.9467 million yuan, a year-on-year decrease of 71.49%, with a gross profit margin of 3.42% [1] Group 3 - In comparison to industry averages, Guo Xin Health's price-to-earnings (P/E) ratio (TTM) is -4720.21, and its static P/E ratio is -129.75, with a market capitalization of 10.353 billion yuan [2] - The industry average P/E ratio (TTM) is 143.51, while the median is 81.52, indicating that Guo Xin Health's valuation metrics are significantly lower than the industry benchmarks [2] - The market capitalization of Guo Xin Health is noted to be 10.353 billion yuan, which is lower than the industry median market capitalization of 53.02 billion yuan [2]

Investment Rating - The industry rating is "Outperform the Market" [5][70]. Core Viewpoints - The report emphasizes the importance of domestic demand and self-sufficiency in the defense and military industry, highlighting the sector's resilience amid external pressures such as trade tensions [4][46]. - The military industry is expected to show strong recovery in 2025, driven by rigid demand and high domestic-driven proportions, making it a sector with significant investment potential [4][46]. - The report suggests focusing on traditional main battle equipment and high-elasticity sectors that will span the "15th Five-Year Plan" period [4][50]. Summary by Sections Industry Performance - The military industry index (801740) decreased by 1.96% from March 31 to April 3, while the CSI 300 index fell by 1.37%, resulting in an underperformance of 0.59 percentage points [19]. - Since May 2024, the military index has increased by 14.36%, outperforming the CSI 300 index, which rose by 7.13%, with a relative excess return of 7.23 percentage points [21]. Market Dynamics - Passive fund sizes and shares in military ETFs have significantly increased, indicating strong confidence in the sector [32][47]. - The military sector's current price-to-earnings ratio (TTM) is 60.8, placing it in the 76.47 percentile, suggesting high allocation value at this time [4][50]. Key Investment Opportunities - Recommended stocks include traditional main battle equipment manufacturers such as AVIC Shenyang Aircraft Corporation and AVIC Xi'an Aircraft Industry Group, as well as companies involved in commercial engines and materials [4][50]. - The report identifies potential high-growth areas such as low-cost drones and controlled nuclear fusion technologies [4][50]. Recent Developments - The report notes significant policy changes affecting the military sector, including new tariffs imposed by the U.S. and corresponding responses from China, which historically have led to increased performance in the defense sector during trade tensions [4][46]. - The military sector's strong performance during previous trade conflicts suggests a pattern of resilience and potential for future growth [4][46].

Company Overview - Suzhou Mediston Medical Technology Co., Ltd. specializes in providing Clinical Information System (CIS) software and overall clinical information solutions, focusing on key areas such as operating rooms, intensive care units, pre-hospital emergency care, and in-hospital emergency services [2] - The company's core product, the DoCare series, leverages advanced mobile internet, IoT technology, and big data models to enhance its competitive edge and professionalism, catering to the high-quality development needs of hospitals in the new era [2] - Mediston's end-users include over 2,400 medical institutions across 32 provinces, autonomous regions, and municipalities, with nearly 1,200 being tertiary hospitals [2] Financial Performance - For the third quarter of 2024, the company reported revenue of 360 million yuan, a year-on-year increase of 2.93%, while net profit was -167.22 million yuan, reflecting a year-on-year decline of 81.64% [3] - The gross profit margin for the company stood at 12.87% [3] Market Position - As of April 1, the company's stock closed at 13.18 yuan, up 1.85%, with a latest price-to-book ratio of 4.40 and a total market capitalization of 4.037 billion yuan [1] - The number of shareholders increased to 29,893, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Industry Context - The company is recognized as a national high-tech enterprise and has established a provincial technology center, emphasizing technological innovation with nearly 600 intellectual property rights [2] - Mediston has undertaken significant national projects, including the "12th Five-Year" 863 program on digital medical engineering and various innovation tasks from the Ministry of Industry and Information Technology [2] - The company aims to lead in the domestic health care AI sector by exploring the application of cutting-edge technologies such as 5G, IoT, and AI models in low-altitude economic scenarios [2]

| 5.现场检查情况 | | | --- | --- | | （1）现场检查次数 | 1次 | | （2）现场检查报告是否按照本所规定报送 | 是 | | （3）现场检查发现的主要问题及整改情况 | 参见"二、保荐机构发现公司存在的 问题及采取的措施"之"5.募集资金 | | | 存放及使用" | | 6.发表独立意见情况 | | | （1）发表独立意见次数 | 9次 | | （2）发表非同意意见所涉问题及结论意见 | 不适用 | | 7.向本所报告情况（现场检查报告除外） | | | （1）向本所报告的次数 | 1次 | | （2）报告事项的主要内容 | 参见"二、保荐机构发现公司存在的 | | | 问题及采取的措施"之"5.募集资金 | | | 存放及使用"之"存在的问题" | | （3）报告事项的进展或者整改情况 | 参见"二、保荐机构发现公司存在的 | | | 问题及采取的措施"之"5.募集资金 | | | 存放及使用"之"采取的措施" | | 8.关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 否 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情 ...

二、公司预算编制基础 四川观想科技股份有限公司 2024 年度财务预算方案 特别提示：本预算为四川观想科技股份有限公司 2024 年度经营 计划的内部管理控制指标，不代表公司 2024 年度盈利预测，不构成 公司对投资者的实质性承诺，能否实现取决于经济环境、市场状况等 多种因素，存在一定的不确定性，敬请投资者注意投资风险。 一、预算编制说明 本预算报告是以经亚太（集团）会计师事务所（特殊普通合伙） 审计的公司 2023 年度财务报告为基础，综合分析公司的市场和业务 拓展计划以及政策变动、行业形势、市场需求等因素对预期的影响， 并考虑公司现时经营能力的前提下，谨慎地对 2024 年度经营情况进 行预测并编制。 2024 年是贯彻落实党的二十大各项战略部署和实施"十四五"规 划的重要一年，是公司智能装备和人工智能两大元年。公司将紧跟国 家战略导向，紧贴市场需求，紧抓数字经济建设机遇，积极响应"以 新质生产力促进高质量发展""以科技创新引领现代化产业体系建设" "深化国防科技工业改革，形成军民融合深度发展"等国家战略，围 绕新形势新任务展开业务布局，持续秉承"智力拥军、共谋打赢"的 核心理念，深耕行业深耕客户，加强 ...